Factors Associated With Clinical Progression to Severe COVID-19 in People With Cystic Fibrosis: A Global Observational Study

Carr, Siobhán; McClenaghan, Elliot; Elbert, Alexander; Faro, Albert; Cosgriff, Rebecca; Abdrakhmanov, O.; Brownlee, K.; Burgel, Pierre‐Régis; Byrnes, Catherine A.; Cheng, Stephanie; Columbo, Carla; Corvol, Harriet; Daneau, Géraldine; Goss, Christopher H.; Gulmans, Vincent; Gutierrez, Hector; Harutyunyan, Satenik; Jung, Anna; Kashirskaya, N.; McKone, Edward F.; Melo, Joel; Middleton, Peter G.; Mondéjar-López, Pedro; Monestrol, Isabelle de; Naehrlich, Lutz; Padoan, Rita; Parker, Megan; Pastor-Vivero, María Dolores; Rizvi, Samar; Ruseckaite, Rasa; Salvatore, Marco; Silva-Filho, Luiz Vicente R. F. da; Vermessen, Nick; Zampoli, Marco; Stephenson, Anne L.; Marshall, Bruce C.

doi:10.2139/ssrn.3990936

Cited by 7 publications

(25 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demographic and clinical characteristics for the cohort are described in Table 1. The average age at enrollment was 12 years (IQR [7][8][9][10][11][12][13][14][15][16][17].…”

Section: Baseline Clinical Characteristics and Serology Testing Resultsmentioning

confidence: 99%

“…[2][3][4] People with cystic fibrosis (PwCF) have chronic lung disease due to altered airway mucus, chronic airway infection, and airway inflammation, and therefore may be at increased risk of COVID-19-related morbidity and mortality. 5 Prior studies have examined clinical outcomes following polymerase chain reaction-confirmed SARS-CoV-2 infection in people with cystic fibrosis (CF), [6][7][8] but because these studies were casebased, they likely underestimated the number of infections while overestimating the frequency of symptoms and severity of disease in PwCF. 9 To date only three studies (one each from Belgium, Germany, and Northern Italy) have attempted to describe SARS-CoV-2 seroprevalence in PwCF.…”

Section: Introductionmentioning

confidence: 99%

“…Prior studies have examined clinical outcomes following polymerase chain reaction‐confirmed SARS‐CoV‐2 infection in people with cystic fibrosis (CF), 6–8 but because these studies were case‐based, they likely underestimated the number of infections while overestimating the frequency of symptoms and severity of disease in PwCF 9 . To date only three studies (one each from Belgium, Germany, and Northern Italy) have attempted to describe SARS‐CoV‐2 seroprevalence in PwCF 10–12 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Seroprevalence and clinical characteristics of SARS‐CoV‐2 infection in children with cystic fibrosis

Hergenroeder

Faino²,

Cogen

et al. 2023

Pediatric Pulmonology

View full text Add to dashboard Cite

BackgroundPeople with cystic fibrosis (PwCF) have chronic lung disease and may be at increased risk of coronavirus disease 2019 (COVID‐19)‐related morbidity and mortality. This study aimed to determine seroprevalence and clinical characteristics of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in children with cystic fibrosis (CF), and to assess antibody responses following SARS‐CoV‐2 infection or vaccination.MethodsChildren and adolescents with CF followed at Seattle Children's Hospital were enrolled between July 20, 2020 and February 28, 2021. SARS‐CoV‐2 serostatus was determined on enrollment at 6 and 11 months (±2 months) for nucleocapsid and spike IgG. Participants completed intake and weekly surveys inquiring about SARS‐CoV‐2 exposures, viral/respiratory illnesses, and symptoms.ResultsOf 125 PwCF enrolled, 14 (11%) had positive SARS‐CoV‐2 antibodies consistent with recent or past infection. Seropositive participants were more likely to identify as Hispanic (29% vs. 8%, p = 0.04) and have pulmonary exacerbations requiring oral antibiotics in the year prior (71% vs. 41%, p = 0.04). Five seropositive individuals (35.7%) were asymptomatic, while six (42.9%) reported mild symptoms, primarily cough and nasal congestion. Antispike protein IgG levels were approximately 10‐fold higher in participants following vaccination compared with participants who had natural infection alone (p < 0.0001) and resembled levels previously reported in the general population.ConclusionsA majority of PwCF have mild or no symptoms of SARS‐CoV‐2 making it difficult to distinguish from baseline respiratory symptoms. Hispanic PwCF may be disproportionately impacted, consistent with racial and ethnic COVID‐19 disparities among the general US population. Vaccination in PwCF generated antibody responses similar to those previously reported in the general population.

show abstract

“…Demographic and clinical characteristics for the cohort are described in Table 1. The average age at enrollment was 12 years (IQR [7][8][9][10][11][12][13][14][15][16][17].…”

Section: Baseline Clinical Characteristics and Serology Testing Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seroprevalence and clinical characteristics of SARS‐CoV‐2 infection in children with cystic fibrosis

Hergenroeder

Faino²,

Cogen

et al. 2023

Pediatric Pulmonology

View full text Add to dashboard Cite

show abstract

“…Uma publicação mais recente e maior, com 1.452 casos de pacientes com FC infectados com SARS-CoV-2, confirmou que a maioria dos pacientes com FC apresentava sintomas leves e boa recuperação após a infecção. (5) No entanto, comorbidades como diabetes relacionado à FC, função pulmonar diminuída e imunossupressão mais uma vez se mostraram fatores de risco para complicações graves. (5) Vários relatos e séries de casos confirmaram a associação de transplante pulmonar em pacientes com FC e formas graves de COVID-19.…”

unclassified

“…(5) No entanto, comorbidades como diabetes relacionado à FC, função pulmonar diminuída e imunossupressão mais uma vez se mostraram fatores de risco para complicações graves. (5) Vários relatos e séries de casos confirmaram a associação de transplante pulmonar em pacientes com FC e formas graves de COVID-19. (6)(7)(8) Esses dados reforçam que a imunossupressão relacionada ao transplante seria um fator contribuinte para um maior risco de complicações do que a própria FC.…”

unclassified

Is cystic fibrosis a risk factor for COVID-19 infection or related complications?

Athanazio

2022

J Bras Pneumol.

View full text Add to dashboard Cite

Cystic fibrosis year in review 2022

Kim,

Lyman,

Savant

2023

Pediatric Pulmonology

View full text Add to dashboard Cite

Remarkable medical advancements have been made for people with cystic fibrosis (CF) in recent years, with an abundance of research continuing to be conducted worldwide. With concern for limitations in access to highly effective CFTR modulators, as well as the recent Coronavirus Disease‐19 pandemic, there has been a consistent effort to understand and improve CF screening, disease burden, diagnosis, and management. Our aim in this review is to present articles from 2022 with an emphasis on clinically relevant studies. We hope this will serve as a broad overview of the research published in the past year.

show abstract

Factors Associated With Clinical Progression to Severe COVID-19 in People With Cystic Fibrosis: A Global Observational Study

Cited by 7 publications

References 113 publications

Seroprevalence and clinical characteristics of SARS‐CoV‐2 infection in children with cystic fibrosis

Seroprevalence and clinical characteristics of SARS‐CoV‐2 infection in children with cystic fibrosis

Is cystic fibrosis a risk factor for COVID-19 infection or related complications?

Cystic fibrosis year in review 2022

Contact Info

Product

Resources

About